Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Nivolumab + Pepinemab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 79||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer, small cell lung cancer, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Pepinemab||VX15/2503||Pepinemab (VX15/2503) is a monoclonal antibody that binds to semaphorin 4D (SEMA4D) and blocks plexin-B1 binding, leading to anti-tumor and immune regulatory activity (PMID: 26446947, PMID: 28642891).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03425461||Phase I||Ipilimumab + Pepinemab Nivolumab + Pepinemab||Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma||Terminated||USA||0|
|NCT03769155||Phase I||Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab Ipilimumab + Nivolumab + Pepinemab||VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma||Recruiting||USA||0|
|NCT03373188||Phase I||Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab||VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer||Recruiting||USA||0|
|NCT03690986||Phase I||Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab||VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer||Recruiting||USA||0|